Clinical Trial Update: AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of AZD2014 plus novel anti-cancer agents for relapsed or refractory diffuse large B-cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• AZD2014 (vistusertib)

Snippet

Sponsor: AstraZeneca | Conditions: Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Module 1: Non-GCB Diffuse Large B-Cell Lymphoma | Phase 1 | Status: WITHDRAWN